ADCAN Pharma Welcomes Visit by Emirates Drug Establishment Director General to Review National Pharmaceutical Manufacturing Readiness
Abu Dhabi, UAE – 16/03/2026
ADCAN Pharma welcomed H.E. Dr. Fatima Al Kaabi, Director General of the Emirates Drug Establishment (EDE), to its pharmaceutical manufacturing facilities in Abu Dhabi as part of EDE’s ongoing field visits to national pharmaceutical manufacturers across the United Arab Emirates.
The visit reflects the UAE leadership’s continued commitment to strengthening the national pharmaceutical sector and ensuring the sustainable availability of safe, high-quality medicines for the community. It also underscores the importance of close collaboration between regulators and local manufacturers in advancing the UAE’s healthcare resilience and supporting national health priorities.
Hamdan Aldahmani, Chairman of ADCAN Pharma, said:
“It is a great honor to welcome H.E. Dr. Fatima Al Kaabi and the leadership of the Emirates Drug Establishment to ADCAN Pharma. Under her visionary leadership, EDE has played a pivotal role in strengthening the UAE’s pharmaceutical ecosystem and supporting the development of resilient local manufacturing capabilities that safeguard national healthcare security. This progress is made possible thanks to the unwavering support and strategic vision of the UAE’s wise leadership, whose commitment to advancing national healthcare and pharmaceutical manufacturing continues to position the country as a regional and global leader in healthcare innovation and resilience.”
H.E. Dr. Fatima Al Kaabi, Director General of the Emirates Drug Establishment, said:
“The pharmaceutical sector in the UAE enjoys stability and readiness thanks to the application of an advanced system that ensures the sustainable availability of medicines to the community according to the highest standards of quality and safety.”
Dr Fatima noted that local pharmaceutical and medical supply manufacturers play a fundamental role in reinforcing the UAE’s drug security and supporting the national economy, adding that close cooperation with these companies has helped guarantee that the country’s strategic stockpile of medicines and medical supplies is secure and sufficient to meet domestic demand.
Al Kaabi added: “The UAE’s pharmaceutical sector is stable and well-prepared, backed by an advanced regulatory system that ensures the steady availability of medicines to the community in line with the highest standards of quality and safety.”
She stated that the Emirates Drug Establishment will spare no effort to create an integrated regulatory environment that supports research and development in the pharmaceutical sector, while also advancing its regulatory and oversight policies in line with global best practices to safeguard the safety, quality and effectiveness of locally manufactured medicines.
Fokion Sinis, Chief Executive Officer of ADCAN Pharma added:
“At ADCAN Pharma, we are proud to contribute to the UAE’s vision of strengthening national pharmaceutical manufacturing and building a resilient healthcare system. In today’s evolving global environment, where pharmaceutical supply chains are facing increasing pressures, local manufacturing plays a critical role in safeguarding the uninterrupted availability of essential medicines.
Our strategic stock levels remain secure and sufficient to meet market needs, and we are working relentlessly alongside the Emirates Drug Establishment and our partners across the healthcare ecosystem to strengthen production capabilities, maintain the highest standards of quality and safety, and ensure that patients across the UAE continue to have reliable access to high-quality medicines.
We are also deeply grateful for the outstanding leadership and continued support of H.E. Dr. Fatima Al Kaabi and the Emirates Drug Establishment, whose guidance and partnership play a vital role in advancing the UAE’s pharmaceutical sector and strengthening the country’s healthcare resilience.”
The visit forms part of the Emirates Drug Establishment’s broader efforts to monitor the readiness of national pharmaceutical manufacturers and ensure the sustainable availability of medicines in line with the highest standards of quality, safety and regulatory oversight.
As the UAE continues to invest in strengthening its national pharmaceutical capabilities, cooperation between regulators and industry remains central to advancing local manufacturing, enhancing production capacity and reinforcing the country’s position as a regional hub for pharmaceutical innovation and supply.
